These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 33674997)

  • 1. Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Neuberger EE; Carlson JJ; Veenstra DL
    Pharmacoeconomics; 2021 Apr; 39(4):477-478. PubMed ID: 33674997
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Hollenack K; Marshall J
    Pharmacoeconomics; 2021 Apr; 39(4):473-475. PubMed ID: 33674999
    [No Abstract]   [Full Text] [Related]  

  • 3. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome.
    Neuberger EE; Carlson JJ; Veenstra DL
    Pharmacoeconomics; 2020 Nov; 38(11):1237-1245. PubMed ID: 32715412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic options for Dravet and Lennox-Gastaut syndrome.
    Verrotti A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1191-1194. PubMed ID: 33297778
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
    CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review.
    Capra S; Narayan SW; Parratt K; Patanwala AE
    J Clin Pharm Ther; 2020 Jun; 45(3):570-572. PubMed ID: 31770462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 15. Lennox-Gastaut syndrome: New treatments and treatments under investigation.
    Auvin S
    Rev Neurol (Paris); 2020 Jun; 176(6):444-447. PubMed ID: 32409177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study.
    Weinstock A; Agarwal N; Farooq O; Cheema Z; Hamilton D; Parrish J
    J Child Neurol; 2019 Jul; 34(8):432-439. PubMed ID: 30913948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse effects of cannabinoids.
    Anciones C; Gil-Nagel A
    Epileptic Disord; 2020 Jan; 22(S1):29-32. PubMed ID: 31941644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol in the Treatment of Epilepsy.
    von Wrede R; Helmstaedter C; Surges R
    Clin Drug Investig; 2021 Mar; 41(3):211-220. PubMed ID: 33559102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and drug interactions of cannabinoids.
    Landmark CJ; Brandl U
    Epileptic Disord; 2020 Jan; 22(S1):16-22. PubMed ID: 31941642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.